Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease

Journal of Neural Transmission, Supplementa

Volumn , Issue 73, 2009, Pages 259-268

  Reksidler, Angela B ^a   Lima, Marcelo M S ^b   Dombrowski, Patrícia A ^a   Barnabé, Gabriela F ^c   Andersen, Monica L ^c   Tufik, Sergio ^c   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Campus Universitário ^*  (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal model; L DOPA; MPTP; Neurotoxicity; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPA; DOPAMINE; TYROSINE 3 MONOOXYGENASE; 3,4 DIHYDROXYPHENYLACETIC ACID; ANTIPARKINSON AGENT; HOMOVANILLIC ACID; LEVODOPA; NEUROTOXIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG INFUSION; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; ANALYSIS OF VARIANCE; ANIMAL; CELL COUNT; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; DRUG INTERACTION; GENE EXPRESSION REGULATION; METABOLISM; MOVEMENT (PHYSIOLOGY); NERVE CELL; PARKINSONISM; PATHOLOGY; RAT; REACTION TIME; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CELL COUNT; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; HOMOVANILLIC ACID; LEVODOPA; MALE; MOVEMENT; NEURONS; NEUROTOXINS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; REACTION TIME; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 77952316608     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-92660-4_21     Document Type: Article

References (40)

1. Alexander T, Sortwell CE, Sladek CD et al (1997) Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa, and dopamine to embryonic mesenphalic dopamine neurons in cultures derived from fisher 344 and Sprague-Dawley donors. Cell Transplantation 6:309-315
2. Basma RB, Morris EJ, Niklas WJ et al (1995) L-DOPA cytotoxicity to PC12 cells in culture is via its autooxidation. J Neurochem 64:825-832
3. Benbir G, Ozekmekci S, Cinar M et al (2006) Features associated with the development of hallucinations in Parkinson's disease. Acta Neurol Scand 114:239-243
4. Bendir G, Özekmekçi S, Apaydin H et al (2006) A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Clin Neurol Neurosurg 108:726-732
5. Braga R, Kouzmine I, Canteras NS et al (2005) Lesion of the substantia nigra pars compacta impairs delayed alternation in a Y-maze in rats. Exp Neurol 192:134-141
6. Broadhurst PL (1960) Experiments in psychogenetics. In: Eisenk HJ (ed) Experiments in personality. Routledge and Kegan Paul, London
7. Da Cunha C, Gevaerd MS, Vital MABF et al (2001) Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 124:9-18
8. Da Cunha C, Angellucci MEM, Canteras NS et al (2002) The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinsońs disease memory disabilities. Cell Mol Neurobiol 22:227-237
9. Fahn S, Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32:804-812
10. Ferro MM, Bellíssimo MI, Anselmo-Franci JA et al (2005) Comparison of bilaterally 6-OHDA-and MPTP-lesioned rats as models of early phase of Parkinson's disease: Histological, neurochemical, motor and memory alterations. J Neurosci Methods 148:78-87
11. Fisher A, Biggs CS, Eradiri O et al (2000) Dual effects of L-3, 4-dihydroxyphenylalanine on aromatic L-amino acid decarboxilase, dopamine release on motor stimulation in the reserpine-treated rat: evidence that behavior is dopamine independent. Neuroscience 95:97-111
12. Golbe LI (1992) Young-onset Parkinson's disease: a clinical review. Neurology 41:168-173
13. Gross CE, Ravenscroft P, Dovero S et al (2003) Pattern of levodopainduced striatal changes is different in normal and MPTP-lesioned mice. J Neurochem 84:1246-1255
14. Guigoni C, Dovero S, Aubert I et al (2005) Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extend and pattern of nigrostriatal lesioning. Eur J Neurosci 22:283-287
15. Konitsiotis S, Tsironis C (2006) Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon? Behav Brain Res 170:337-341
16. Kostrzewa RM, Nowak P, Kostrzewa JP et al (2005) Peculiarities of L-DOPA treatment of Parkinson's disease. Amino Acids 28:157-164
17. Lima MMS, Reksidler AB, Zanata SM et al (2006) Different parkinsonism models produce a time dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101:117-125
18. Lima MMS, Andersen ML, Reksidler AB et al (2007) The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2: e513
19. Lowry OH, Rosebrough NJ, Farr AL et al (1951) Protein measurement with the Folin protein reagent. J Bio Chem 193:265-275
20. Lundblad M, Picconi B, Lindgreen H et al (2004) A model of L-dopainduced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110-123
21. Maeda T, Cheng N-N, Kume T et al (1997) L-dopa neurotoxicity is mediated by glutamate release in cultured striatal neurons. Brain Res 771:159-162
22. Miyawaki E, Lyons K, Pahwa R et al (1997) Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 20:523-530
23. Miyoshi E, Wietzikoski S, Camplessei M et al (2002) Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 58:41-47
24. Muller T, Hefter H, Hueber R et al (2004) Is levodopa toxic? J Neurol 251:44-46
25. Myers CS, Halladay AK, Widmer DA et al (1999) Neurotoxic effects of amphetamine plus L-DOPA. Prog Neuro-Psychopharmacol Biol Psychiatry 23:731-740
26. Mytilineou C, Walker RH, Jnobaptiste R et al (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304:792-800
27. Olanow CW, Gauger BA, Cedarbaum MJ (1991) Temporal relantionships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinsońs disease. Ann Neurol 29:556-569
28. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates, 5th edn. Academic, San Diego, CA
29. Perry JC, Hipólide DC, Tufik S et al (2005) Intra-nigral MPTP lesion in rats: behavioral and autoradiography studies. Exp Neurol 195:322-329
30. Quinn N, Critchley P, Marsden CD (1987) Young-onset Parkinson's disease. Mov Disord 2:73-91
31. Rajput AH (2001) Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 8:95-100
32. Reksidler AB, Lima MMS, Zanata S Metal (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560(2):163-175
33. Reksidler AB, Lima MMS, Dombrowski P et al (2008) Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Methods 167:268-277
34. Sarre S, Vandeneed D, Ebinger G et al (1998) Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists. J Neurochem 70:1730-1739
35. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 123:2297-2305
36. Sundstrom E, Fredriksson A, Archer T (1990) Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinsońs disease. Brain Res 528:181-188
37. Tedroff JM (1997) The neuroregulatory properties of L-DOPA. A review of the evidence and potential role in the treatment of Parkinsońs disease. Rev Neurosci 8:195-204
38. Thobois S, Delamarre-Damier F, Derkinderen P (2005) Treatment of motor dysfunctions in Parkinson's disease: an overview. Clin Neurol Neurosurg 107:269-281
39. von Bohlen und Halbach O (2005) Animal models of Parkinsońs disease. Neurodegener Dis 2:313-320
40. Ziv I, Zilkha-Falb R, Offen D et al (1997) Levodopa induces apoptosis in cultured neuronal cells-a possible accelerator of nigrostriatal degeneration in Parkinsońs disease? Mov Disord 12:17-23